H. Park

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Komal Jhaveri, L.D. Eli, Hans Wildiers et al. · Annals of Oncology · 2023 · 61 citations · Full text

Medicine, Oncology, Pharmacology +17

1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen

Geoffrey Y. Ku, Maria Di Bartolomeo, E.C. Smyth et al. · Annals of Oncology · 2022 · 30 citations · Full text

Medicine, Oncology, Metastasis +16

OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer

Junji Tsurutani, H. Park, Toshihiko Doi et al. · Journal of Thoracic Oncology · 2018 · 26 citations · Full text

Medicine, Oncology, Molecular Oncology +7

FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies

B. Li, Leena Gandhi, Benjamin Besse et al. · Journal of Thoracic Oncology · 2021 · 17 citations

Medicine, Oncology, Pharmacology +12

1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A

Daniel V.T. Catenacci, H. Park, Byoung Yong Shim et al. · Annals of Oncology · 2021 · 14 citations

Medicine, Molecular Medicine, Oncology +12